We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alvocidib Biomarker-driven Phase 2 AML Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02520011
Recruitment Status : Recruiting
First Posted : August 11, 2015
Last Update Posted : January 15, 2018
Sponsor:
Information provided by (Responsible Party):

August 6, 2015
August 11, 2015
January 15, 2018
March 14, 2016
June 2018   (Final data collection date for primary outcome measure)
Complete Remission (CR) rate = Percentage of patients achieving CR [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT02520011 on ClinicalTrials.gov Archive Site
  • Overall Survival (OS) Rate [ Time Frame: 2 years ]
    Day 1 until death from any cause
  • Combined CR Rate = Percentage of patients achieving CR, CRi, CRp [ Time Frame: 3 months ]
  • Combined Response Rate = Percentage of patients achieving CR, CRi, CRp, PR [ Time Frame: 3 months ]
  • Rate of Stem Cell Transplantation [ Time Frame: 6 months ]
  • Event-Free Survival [ Time Frame: 2 years ]
  • Combined CR Rate = Percentage of patients achieving CR, CRi, CRp [ Time Frame: 3 months ]
  • Combined Response Rate = Percentage of patients achieving CR, CRi, CRp, PR [ Time Frame: 3 months ]
  • Event-Free Survival [ Time Frame: 2 years ]
  • Relapse-Free Survival [ Time Frame: 2 years ]
Mortality [ Time Frame: 30 and 60 days ]
Same as current
 
Alvocidib Biomarker-driven Phase 2 AML Study
A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With an Exploratory Arm in Patients With Newly Diagnosed High-Risk AML
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) to FLAM compared to AM treatment in refractory or relapsed AML patients with demonstrated NOXA BH3 priming of ≥ 40% by mitochondrial profiling in bone marrow.

In Stage 1 of the study, all eligible AML patients with demonstrated NOXA BH3 priming of ≥ 40% by mitochondrial profiling in bone marrow will receive treatment with alvocidib, cytarabine and mitoxantrone [ACM ('FLAM') regimen].

In Stage 2, all eligible AML patients with demonstrated NOXA BH3 priming of ≥ 40% by mitochondrial profiling in bone marrow will be randomized 1:1 to receive either treatment with ACM or CM (cytarabine and mitoxantrone).

In the NDHR exploratory arm, all eligible patients with newly diagnosed high-risk (NDHR) AML with NOXA BH3 priming ≥40% by mitochondrial profiling in bone marrow will receive treatment with ACM.

In the NOXA exploratory arm, all eligible AML patients with demonstrated NOXA BH3 priming of ≥ 30 - 39% by mitochondrial profiling in bone marrow will receive treatment with ACM.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Acute Myeloid Leukemia
  • Drug: Alvocidib
    Other Name: flavopiridol
  • Drug: Cytarabine
    Other Name: ara-c
  • Drug: Mitoxantrone
    Other Name: mitoxantrone hydrochloride
  • Experimental: ACM (Stage 1 / Stage 2)
    A: alvocidib (formerly flavopiridol), 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
    Interventions:
    • Drug: Alvocidib
    • Drug: Cytarabine
    • Drug: Mitoxantrone
  • Active Comparator: CM (Stage 2)
    C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
    Interventions:
    • Drug: Cytarabine
    • Drug: Mitoxantrone
  • Experimental: Exploratory Arm - NDHR
    A: alvocidib (formerly flavopiridol), 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
    Interventions:
    • Drug: Alvocidib
    • Drug: Cytarabine
    • Drug: Mitoxantrone
  • Experimental: Exploratory Arm - NOXA
    A: alvocidib (formerly flavopiridol), 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
    Interventions:
    • Drug: Alvocidib
    • Drug: Cytarabine
    • Drug: Mitoxantrone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
119
December 2019
June 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Be between the ages of ≥18 and ≤65 years
  2. Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometry
  3. Be in first relapse (within 24 months of CR) or have primary refractory AML (refractory to initial induction therapy using 1 or 2 cycles of intensive anthracycline/cytarabine ± etoposide or cladribine induction) or have newly diagnosed high-risk AML as defined in this protocol.
  4. Demonstrate NOXA BH3 priming of ≥40% by mitochondrial profiling in bone marrow or 30 - 39% for NOXA Exploratory Arm.
  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2
  6. Have a serum creatinine level ≤1.8 mg/dL
  7. Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN)
  8. Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)
  9. Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
  10. Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for 6 months after completion of study therapy.
  11. Be able to comply with the requirements of the entire study.
  12. Provide written informed consent prior to any study related procedure.

Exclusion Criteria:

  1. Received more than 2 cycles of induction therapy for AML. Investigational agents as part of front-line therapy for AML may by acceptable following discussion with the Medical Monitor. Hydroxyurea is permitted (see #5 below).
  2. Received any previous treatment with alvocidib or any other CDK inhibitor
  3. Received a hematopoietic stem cell transplant within the previous 2 months
  4. Have clinically significant graft versus host disease (GVHD), or GVHD requiring initiation or escalation of treatment within the last 21 days
  5. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.
  6. Received >360 mg/m2 equivalents of daunorubicin
  7. Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #5 above)
  8. Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor.
  9. Diagnosed with acute promyelocytic leukemia (APL, M3)
  10. Have active central nervous system (CNS) leukemia
  11. Have evidence of uncontrolled disseminated intravascular coagulation
  12. Have an active, uncontrolled infection
  13. Have other life-threatening illness
  14. Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia
  15. Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol.
  16. Are pregnant and/or nursing
  17. Have received any live vaccine within 14 days prior to first study drug administration.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact: Judy Costas, BSN 3616499176 jcostas@toleropharma.com
Canada,   United States
 
 
NCT02520011
TPI-ALV-201
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Tolero Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Not Provided
Study Director: Stephen Anthony, DO Tolero Pharmaceuticals
Tolero Pharmaceuticals, Inc.
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP